Hillsdale Investment Management Inc. Sells 33,520 Shares of Guardant Health, Inc. $GH

Hillsdale Investment Management Inc. cut its stake in Guardant Health, Inc. (NASDAQ:GH) by 21.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 122,380 shares of the company’s stock after selling 33,520 shares during the quarter. Hillsdale Investment Management Inc. owned 0.10% of Guardant Health worth $12,500,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at about $27,000. Chesapeake Asset Management LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Guardant Health in the 4th quarter valued at about $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at about $35,000. Finally, First Pacific Financial bought a new stake in shares of Guardant Health in the 4th quarter valued at about $43,000. 92.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Piper Sandler set a $127.00 price target on Guardant Health in a research note on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Raymond James Financial reaffirmed an “outperform” rating and issued a $129.00 price target on shares of Guardant Health in a research note on Monday, February 23rd. Barclays upped their price target on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, Wells Fargo & Company increased their target price on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $129.79.

Insider Buying and Selling at Guardant Health

In related news, insider Chris Freeman sold 24,406 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the sale, the insider directly owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. This represents a 28.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Amirali Talasaz sold 210,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the sale, the chief executive officer directly owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 332,244 shares of company stock worth $36,156,026 in the last quarter. Company insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ GH opened at $129.69 on Friday. The business has a 50 day simple moving average of $95.08 and a 200 day simple moving average of $99.94. Guardant Health, Inc. has a 52-week low of $38.03 and a 52-week high of $133.97. The stock has a market cap of $17.20 billion, a price-to-earnings ratio of -38.26 and a beta of 1.48.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.